Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 12:05 AM
Ignite Modification Date:
2025-12-25 @ 10:04 PM
NCT ID:
NCT03406858
Group ID:
EG000
Title:
Treatment (Pembrolizumab, HER2Bi-armed Activated T Cells)
Description:
Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
HER2Bi-Armed Activated T Cells: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pembrolizumab: Given IV
Deaths Number Affected:
9
Deaths Number At Risk:
None
Serious Number Affected:
7
Serious Number At Risk:
14
Other Number Affected:
14
Other Number At Risk:
14
Study:
NCT03406858
Results Section:
NCT03406858
Adverse Events Module:
NCT03406858